Nuclear Medicine and Molecular Imaging

  • 제40권2호
  • /
  • Pages.90-95
  • /
  • 2006
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

신경내분비종양의 방사성핵종 치료

Review of Radionuclide Treatment for Neuroendocrine Tumors

  • 정환정 (전북대학교 의과대학 핵의학교실)
  • Jeong, Hwan-Jeong (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
  • 발행 : 2006.04.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Neuroendocrine tumors (NETs) consist of a heterogeneous group of tumors that are able to uptake neuroamine and/or specific receptors, such as somatostatin receptors, which can play important roles of the localization and treatment of these tumors. When considering therapy with radionuclides, the best radioligand should be carefully investigated. $^{131}I$-MIBG and beta-particle emitter labeled somatostatin analogs are well established radionuclide therapy modalities for NETs. $^{111}In,\;^{90}Y\;and\;^{177}Lu$ radiolabeled somatostatin analogues have been used for treatment of NETs. Further, radionuclide therapy modalities, for example, radioimmunotherapy, radiolabeled peptides such as minigastrin are currently under development and in different phases of clinical investigation. for all radionuclides used for therapy, long-term and survival statistics are not yet available and only partial tumour responses have been obtained using $^{131}I$-MIBG and $^{111}In$-octreotide. Experimental results using $^{90}Y$-DOTA-lanreotide as well as $^{90}Y-DOTA-D-Phe1-Tyr^3-octreotide$ and/or $^{177}Lu-DOTA-Tyr^3-octreotate$ have indicated the possible clinical potential of radionuclides receptor-targeted radiotherapy it may be hoped that the efficacy of radionuclide therapy will be improved by co-administration of chemotherapeutic drugs whose antitumoral properties may be synergistic with that of irradiation.

키워드

참고문헌

  1. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60
  2. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann. ncol 2001;12(Suppl): S51-S61
  3. Chatal JF, Le Bodic MF, Kraeber-Bodere F, Rousseau C, Resche I. Nuclear medicine applications for neuroendocrine tumors. World J. Surg 2000;24:1285-9 https://doi.org/10.1007/s002680010213
  4. Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000;44:3-12
  5. Caplin ME, Buscombe JR, Hilson AJ. Carcinoid tumour. Lancet 1998;352:799-805 https://doi.org/10.1016/S0140-6736(98)02286-7
  6. Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000;44:22-41
  7. Troncone L, Rufini V. $^{131}$I-MIBG therapy of neural crest tumours (review). Anticancer Res 1997;17:1823-31
  8. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with ($^{131}$I-meta-iodobenzylguanidine ($^{131}$I mIBG). Clin Endocrinol 2001;55:47-60 https://doi.org/10.1046/j.1365-2265.2001.01309.x
  9. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine ($^{131}$I-MIBG): a comprehensive review of 116 reported patients. J Endocrinoll Invest 1997;20:648-58 https://doi.org/10.1007/BF03348026
  10. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobezylguanidine (MIBG). Nucl Med Comm 1992;13:513-21 https://doi.org/10.1097/00006231-199207000-00006
  11. Khafagi FA, Shapiro B, Fig LM. Labetolol reduces $^{131}$I MIBG uptake by pheochromocytoma and normal tissue. J Nucl Med 1989;30:481-9
  12. Treatment of metastatic pheochromocytoma and paraganglioma with $^{131}$I-meta-iodobenzylguanidine (MIBG). Endocrinologist 2003;13:1-13 https://doi.org/10.1097/00019616-200301000-00001
  13. Chatal JF, Le Bodic MF, Kraeber-Bodere F, Rousseau C, Resche I. Nuclear medicine applications for neuroendocrine tumors. World J Surg 2000;24:1285-9 https://doi.org/10.1007/s002680010213
  14. Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 1999;43:344-55
  15. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-67 https://doi.org/10.1007/BF03350317
  16. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98 https://doi.org/10.1006/frne.1999.0183
  17. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic andradiotherapeutic use. Eur J Nucl Med 2000;27:273-82 https://doi.org/10.1007/s002590050034
  18. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-9
  19. Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur J Pharmacol 1998;345:103-10 https://doi.org/10.1016/S0014-2999(97)01618-X
  20. Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, et al. In vitro and in vivo studies of three radiolabelled somatostatin analogues: $^{123}$I-octreotide (OCT), $^{123}$I-Tyr-3-OCT and $^{111}$In-DTPA- D-Phe-1-OCT. Eur J Nucl Med 1996;23:1388-99 https://doi.org/10.1007/BF01367597
  21. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-8
  22. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995;36:623-7
  23. Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of $^{111}$In-DOTA-Tyr3-octreotide and $^{111}$In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-7
  24. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1:242-4
  25. Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Fuger B, Li SR, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol 2001;12(Suppl 2); S41-S45
  26. Kwekkeboom DJ, Kooij PP, Bakker WH, van der Pluijm ME, Srinivasan A, Erion J, et al. Lu-177-DOTA-Tyr3-octreotate: comparison with In-111-DTPA-octreotide in patients. Eur J Nucl Med 2001;28:1319-25 https://doi.org/10.1007/s002590100574
  27. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with $^{111}$In-DTPA-D-Phe1- and $^{123}$I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31 https://doi.org/10.1007/BF00181765
  28. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9 https://doi.org/10.1007/s002590100502
  29. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann NY Acad Sci 2004;1014:234-45 https://doi.org/10.1196/annals.1294.026
  30. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [$^{177}$Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33 https://doi.org/10.1002/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L
  31. Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;67:1437-9 https://doi.org/10.1038/bjc.1993.266
  32. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388-92
  33. Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using $^{131}$I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 2000;41:93-103
  34. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999;10:995-1008 https://doi.org/10.1089/10430349950018391
  35. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002;62:6124-31
  36. Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, et al. Characterization of $^{123}$I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 2001;91:789-96 https://doi.org/10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.0.CO;2-K
  37. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003;14:1274-7 https://doi.org/10.1093/annonc/mdg344
  38. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, et al. Iodine-123-Vascular Endothelial Growth Factor-165 (123I-VEGF165): Biodistribution, Safety and Radiation Dosimetry in Patients with Pancreatic Carcinoma. Q J Nucl Med Mol Imaging 2004;48: 198-206
  39. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated $^{90}$Y labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004;58:1215-27 https://doi.org/10.1016/j.ijrobp.2003.10.057
  40. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14 https://doi.org/10.1530/eje.0.1410001
  41. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nuc Med Mol Imaging 2003;30:463-469 https://doi.org/10.1007/s00259-002-1107-8
  42. Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol 2002;29:152-9 https://doi.org/10.1053/sonc.2002.31672
  43. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637-44